# reload+after+2024-01-23 17:44:34.180002
address1§14 Einstein Street
city§Ness Ziona
zip§7403618
country§Israel
phone§972 8 662 3301
fax§972 8 631 2981
website§https://www.enlivex.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Shai  Novik M.B.A.', 'age': 57, 'title': 'Executive Chairman', 'yearBorn': 1966, 'fiscalYear': 2019, 'totalPay': 528000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Oren  Hershkovitz Ph.D.', 'age': 46, 'title': 'Chief Executive Officer', 'yearBorn': 1977, 'fiscalYear': 2019, 'totalPay': 273600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Dror  Mevorach M.D.', 'age': 67, 'title': 'Founder and Chief Scientific & Medical Officer', 'yearBorn': 1956, 'fiscalYear': 2019, 'totalPay': 180000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Shachar  Shlosberger CPA', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2019, 'totalPay': 126000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Veronique  Amor-Baroukh', 'title': 'Senior Director of Operations', 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sigal  Arad', 'title': 'Director of HR', 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1577750400
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.986
currency§USD
dateShortInterest§1702598400
forwardEps§-0.86
exchange§NCM
quoteType§EQUITY
shortName§Enlivex Therapeutics Ltd.
longName§Enlivex Therapeutics Ltd.
firstTradeDateEpochUtc§1406813400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b74cb9f5-e16c-38f4-8a35-7f19c807ad7d
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§12.0
targetMeanPrice§12.0
targetMedianPrice§12.0
recommendationKey§none
numberOfAnalystOpinions§1
quickRatio§7.029
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
